Adoptive cell therapies, particularly CAR T‐cells, are among these promising immunotherapies gaining interest, after intraventricularly applied CAR T‐cells engineered to target the EGFR variant III using a second‐generation CAR and also engineered to secrete a wildtype EGFR‐targeting T‐cell engaging antibody molecule, have shown dramatic and rapid radiological tumor response in three patients with recurrent glioblastoma. The gene discussed is EGFR; the disease is neoplasm.